WSJ: Planned Parenthood facing ‘potentially dire future’
Caroline MolloyPlanned Parenthood may be looking at a “dire future” as it wrestles with political opposition, shifting mission focuses, and profound financial difficulties, according to a July 18 article in the Wall Street Journal.
In her piece for the Wall Street Journal, Pamela Paul, who formerly was an opinion columnist for the New York Times, observed that the nation’s largest abortion provider has pivoted to spending much of its time and energy on pro-“transgender”-related efforts. Today, in a document for patients, the abortion giant bills itself as “the second largest provider of hormone therapy” in the US.
Planned Parenthood does not make numbers on “gender transitions” publicly available, according to Paul. However, she reports that the Manhattan Institute, a conservative think tank, released an analysis of insurance data showing that more than 40,000 patients went to Planned Parenthood in 2023 for “gender medicine.” Approximately 40% of these patients were 18 to 22 years old.
From 2017 to 2023, Planned Parenthood treated at least 12,000 12- to 17-year-olds for gender dysphoria, according to the Manhattan Institute’s analysis.
Focus on “gender medicine” has become so central to Planned Parenthood’s identity that it “no longer positions itself as the leading healthcare provider for women and has largely stopped referring to women on its website and in policy statements,” Paul observed.
Planned Parenthood now usually uses the term “pregnant people” to be “inclusive,” but this approach has brought concern among some, including former Planned Parenthood President Pamela Maraldo.
“I don’t understand the national office’s thinking in not allowing anyone to talk about women’s health anymore,” Maraldo said, according to the Wall Street Journal. “These really, really left-wing ideological postures are to me just as off-putting as they are on the right when they’re counter to basic Americans’ common sense.”
The company’s pro-“transgender” pivot has also garnered criticism due to its protocol regarding prescribing cross-sex hormones.
According to the Wall Street Journal, patients do not need a professional diagnosis to obtain cross-sex hormones at Planned Parenthood — all that Planned Parenthood’s patient guidelines require for a same-day prescription is a 30-minute consultation with a staff member, which can be done in person or remotely.
Even some who support the use of cross-sex hormones have been critical of what they see as Planned Parenthood’s laissez-faire approach, such as Laura Edwards-Leeper, who helped found the US’ first pediatric “gender” clinic.
Edwards-Leeper, who was instrumental in developing standards of care for the transgender advocacy group World Professional Association for Transgender Health (WPATH), shared that she has been taken aback by her young patients’ descriptions of how easy it has been to obtain hormone treatments from Planned Parenthood.
“It really seems that their protocol is substandard and lacks the rigor necessary for a life-altering intervention,” Edwards-Leeper said, according to the Wall Street Journal.
